SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharma rises on getting long term credit rating upgraded by ICRA

26 Aug 2022 Evaluate

Torrent Pharmaceuticals is currently trading at Rs. 1545.30, up by 10.25 points or 0.67% from its previous closing of Rs. 1535.05 on the BSE.

The scrip opened at Rs. 1540.00 and has touched a high and low of Rs. 1567.35 and Rs. 1540.00 respectively. So far 4924 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1652.23 on 31-Dec-2021 and a 52 week low of Rs. 1242.50 on 12-May-2022.

Last one week high and low of the scrip stood at Rs. 1570.75 and Rs. 1510.00 respectively. The current market cap of the company is Rs. 52393.05 crore.

The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 20.81% and 7.95% respectively.

Credit rating agency -- ICRA has upgraded the long term credit rating of banking facilities and non-convertible debentures of Torrent Pharmaceuticals to ‘AA+/Stable’ from ‘AA/Positive’. ICRA has reaffirmed its rating on commercial paper programme at ‘Al+’.

The upgrade in Torrent Pharmaceutical’s (TPL) long-term rating factors strong business position and performance in its key markets, India, Brazil and ROW (rest of the world), offsetting some moderation in performance witnessed in some other key markets (USA and Germany) in FY2022 and Q1 FY2023.

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharma Share Price

4178.85 22.50 (0.54%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×